The company’s product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, which is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients.
The company’s planned registrational Phase 3 clinical trial of entospletinib in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin-dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in Phase 1/2 clinical trial.
The company is in Barcelona this week to present preclinical data demonstrating that Kronos Bio’s internally discovered oral CDK9 inhibitor, KB-0742 induced regressions in a preclinical model of MYCN-amplified neuroblastoma tumors and inhibited growth in patient-derived xenograft models of transcriptionally addicted Ewing sarcoma and alveolar rhabdomyosarcoma.
The $25 Goldman Sachs target price compares with a $20.20 consensus and a share price of $2.75 on Friday. Hitting the Goldman Sachs target would be an 800% gain.
Rent the Runway
This may be an off-theadar idea, but the upside potential is massive. Rent the Runway Inc. (NASDAQ: RENT) rents designer dresses, clothing and accessories for women through its stores and online platform. The company offers ready-to-wear, workwear, denim, casual, maternity, outerwear, blouses, knitwear, loungewear, activewear, skiwear, evening wear and kidswear products. It also offers jewelry, handbags, home goods and other accessories.
The stock has been absolutely mauled since it went public last October, and insiders have continued to buy shares during the freefall. The good news for investors looking at shares now is the company has increased its subscriber numbers substantially and has over 2.5 million lifetime customers.
The $6 price target at Goldman Sachs is less than the $7.20 consensus target. The stock traded at $1.75 on Friday. Trading to the Goldman Sachs target would be a gain of more than 240%.
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While clearly not suited for all investors, they are not penny stocks with absolutely no track record or liquidity, and with Goldman Sachs very bullish on all of them, they could be poised to move much higher.
Originally published at 24/7 Wall St.
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
